Exclusive Summary

• The product has passed China's generic drug consistency evaluation, indicating high pharmaceutical quality and strong potential for international compliance.
• As a WHO essential medicine, diprophylline maintains a steady global market demand for respiratory diseases, especially in low- and middle-income countries.
• Compared to more expensive imported or originator products, Chinese-manufactured diprophylline injection offers significant cost advantages, improving drug accessibility and reducing healthcare burdens.
• The injectable formulation provides rapid onset of action, making it irreplaceable in emergency and severe patient care settings, particularly in resource-limited regions of developing countries.

Asset Materials

Contact Us for Full Materials